Pharvaris N.V. (PHVS)

Last Closing Price: 2.25 (2022-12-06)

Company Description

Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated indications. Pharvaris N.V. is based in ZUG, Switzerland.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-50.56M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.32
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -24.67%
Return on Assets (Trailing 12 Months) -23.48%
Current Ratio (Most Recent Fiscal Quarter) 12.85
Quick Ratio (Most Recent Fiscal Quarter) 12.85
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $7.62
Earnings per Share (Most Recent Fiscal Quarter) $-0.40
Earnings per Share (Most Recent Fiscal Year) $-1.66
Diluted Earnings per Share (Trailing 12 Months) $-1.87
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 31.84M
Free Float --
Market Capitalization $64.32M
Average Volume (Last 20 Days) 0.05M
Beta (Past 60 Months) -0.77
Percentage Held By Insiders (Latest Annual Proxy Report) --
Percentage Held By Institutions (Latest 13F Reports) 70.21%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%